Broad-spectrum Cytokeratin

Broad-spectrum cytokeratin refers to a group of antibody stains (such as AE1/AE3, CAM 5.2, and MNF116) that detect a wide range of keratin proteins found in epithelial cells and mesothelial cells. Pathologists use these stains on biopsy tissue to confirm that a tumor is of epithelial or mesothelial origin rather than, for example, a lymphoma, sarcoma, or melanoma. In suspected mesothelioma, a positive broad-spectrum cytokeratin stain is one of the first and most important findings supporting the diagnosis.

Origin

The term combines "cytokeratin" — from Greek kytos (cell) and keras (horn), referring to the keratin filaments that give epithelial cells their structure — with "broad-spectrum," meaning the antibody cocktail recognizes many keratin subtypes at once. These immunohistochemical stains came into routine diagnostic use in the 1980s as monoclonal antibody technology matured.

Significance in Asbestos Context

For patients facing a possible mesothelioma diagnosis, broad-spectrum cytokeratin is usually the gateway stain on a biopsy report. Mesothelioma cells almost always stain strongly positive, which helps distinguish mesothelioma from metastatic cancers of non-epithelial origin and from benign reactive tissue. It also helps pathologists identify sarcomatoid mesothelioma, a spindle-cell subtype that can look like a sarcoma under the microscope but retains keratin expression, which is a crucial clue. Because a confident mesothelioma diagnosis is foundational to both treatment planning and any legal claim, patients should make sure their pathology report documents cytokeratin staining along with the mesothelial-specific markers (such as calretinin, WT-1, and D2-40) that follow.

Example Sentence

The pathology report noted that the pleural biopsy was diffusely positive for broad-spectrum cytokeratin (AE1/AE3), which ruled out lymphoma and supported the working diagnosis of sarcomatoid mesothelioma.

Related Terms

Immunohistochemistry, Calretinin, WT-1, Sarcomatoid Mesothelioma, Pleural Biopsy, Epithelioid Mesothelioma

Notes

• Ask your pathologist or oncologist which specific cytokeratin antibodies were used (AE1/AE3 and CAM 5.2 are the most common) and whether the staining pattern was diffuse or focal. This detail can matter for subtype classification.
• If your initial biopsy is negative for broad-spectrum cytokeratin, ask whether mesothelioma has truly been excluded or whether additional tissue, deeper sections, or a second-opinion review (such as at the U.S.–Canadian Mesothelioma Reference Panel) is warranted.
• Preserve copies of the full pathology report, including the immunohistochemistry panel, and request that the original tissue blocks be retained. These may be needed for expert review in both medical second opinions and a legal claim.
• Sarcomatoid mesothelioma can stain only weakly or focally for cytokeratin; if your tumor has spindle-cell features, ask whether multiple keratin antibodies were tried before any non-mesothelioma diagnosis is accepted.